Since PSAP and PGRN are emerging targets for therapeutic development in FTLD, and therapies against negative symptoms are lacking in schizophrenia, it is highly relevant to study PSAP and PGRN levels in schizophrenia. This evidence concerns the gene PSAP and schizophrenia.